Article Information
History
- November 4, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Kevin M. Flanigan, MD1,3,4,*,
- Megan A. Waldrop, MD1,2,
- Paul T. Martin, PhD1,3,
- Roxane Alles, PhD1,
- Diane M. Dunn, BS6,
- Lindsay N. Alfano, DPT1,
- Tabatha R. Simmons, PhD1,
- Melissa Moore-Clingenpeel, MS2,5,
- John Burian, MS2,
- Sang-Cheol Seok, PhD2,
- Robert B. Weiss, PhD6 and
- Veronica J. Vieland, PhD2,3,5
- 1The Center for Gene Therapy, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio
- 2the Battelle Center for Mathematical Medicine, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio
- 3The Departments of Pediatrics, The Ohio State University, Columbus, Ohio
- 4The Departments of Neurology, The Ohio State University, Columbus, Ohio
- 5The Departments of Statistics, The Ohio State University, Columbus, Ohio
- 6The Department of Human Genetics, University of Utah, Salt Lake City, Utah
- ↵*Corresponding Author: Kevin M. Flanigan, MD, Center for Gene Therapy, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH 43209, kevin.flanigan{at}nationwidechildrens.org
Posted November 04, 2021.
A genome-wide association analysis of loss of ambulation in dystrophinopathy patients suggests multiple candidate modifiers of disease severity
